A Biosafety Level 2 Mouse Model for Studying Betacoronavirus-Induced Acute Lung Damage and Systemic Manifestations

Ana Cláudia dos Santos Pereira Andrade, a, Gabriel Henrique Campolina-Silva, b Celso Martins Queiroz-Junior, a Leonardo Camilo de Oliveira, a Larisse de Souza Barbos a Lacer da, a Jordane Clarisse Pimenta Gaggino, a Filipe Resende Oliveira de Souza, a Ian de Meira Chaves, a Ingredy Beatriz Passos, a Danielle Cunha Teixeira, a Paloma Graziele Bittencourt-Silva, a Priscila Aparecida Costa Valadão, a Leonardo Rossi-Oliveira, a Maisa Mota Antunes, a André Felipe Almeida Figueiredo, a Natália Teixeira Wnuk, a Jairo R. Temerozo, a,d André Costa Ferreira, b h Allysson Cramer, b Cleida Aparecida Oliveira, a Ricardo Durães-Carvalho, a Clarice Weis Arns, a Pedro Pires Goulart Guimarães, d Guilherme Mattos Jardim Costa, a Gustavo Batista de Menezes, a Cristina Guatimosim, a Glauer Santos Ferreira da Silva, d Thiago Moreno L. Souza, a,b, Breno Rocha Barrioni, b Marivalda de Magalhães Pereira, b Lilândia Pires de Sousa, b Mauro Martins Teixeira, b Vivian Vasconcelos Costa, a,b,a,b

aDepartment of Morphology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
bDepartment of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
cDepartment of Microbiology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
dDepartment of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
 eLaboratory on Thymus Research, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
fLaboratory for Thymus Research, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
 gNational Institute for Science and Technology on Neuroimmunomodulation, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
hImmunopharmacology Laboratory, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
iLaboratório de Pesquisas Pré-clínicas, Universidade Iguaçu (UNIG), Rio de Janeiro, RJ, Brazil
jLaboratory of Virology, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
kDepartment of Clinical and Toxicological Analysis, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
lDepartment of Metallurgical Engineering and Materials, Federal University of Minas Gerais, School of Engineering, Belo Horizonte, Brazil
mDepartment of Pathology and Toxicology, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

A biosafety level 2 mouse model for studying betacoronavirus-induced acute lung damage and systemic manifestations

ABSTRACT The emergence of life-threatening zoonotic diseases caused by betacoronaviruses, including the ongoing coronavirus disease 19 (COVID-19) pandemic, has highlighted the need for developing preclinical models mirroring respiratory and systemic pathophysiological manifestations seen in infected humans. Here, we showed that C57BL/6J wild-type mice intranasally inoculated with the murine betacoronavirus murine hepatitis coronavirus 3 (MHV-3) develop a robust inflammatory response leading to acute lung injuries, including alveolar edema, hemorrhage, and fibrin thrombosis. Although such histopathological changes seemed to resolve as the infection advanced, they efficiently impaired respiratory function, as the infected mice displayed restricted lung distention and increased respiratory frequency and ventilation. Following respiratory manifestation, the MHV-3 infection became systemic, and a high virus burden could be detected in multiple organs along with morphological changes. The systemic manifestation of MHV-3 infection was also marked by a sharp drop in the number of circulating platelets and lymphocytes, besides the augmented concentration of the proinflammatory cytokines interleukin 1 beta (IL-1β), IL-6, IL-12, gamma interferon (IFN-γ), and tumor necrosis factor (TNF), thereby mirroring some clinical features observed in moderate and severe cases of COVID-19. Importantly, both respiratory and systemic changes triggered by MHV-3 infection were greatly prevented by blocking TNF signaling, either via genetic or pharmacologic approaches. In line with this, TNF blockage also diminished the infection-mediated release of proinflammatory cytokines and virus replication of human
epithelial lung cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Collectively, results show that MHV-3 respiratory infection leads to a large range of clinical manifestations in mice and may constitute an attractive, lower-cost, biosafety level 2 (BSL2) in vivo platform for evaluating the respiratory and multiorgan involvement of betacoronavirus infections.

**IMPORTANCE** Mouse models have long been used as valuable in vivo platforms to investigate the pathogenesis of viral infections and effective countermeasures. The natural resistance of mice to the novel betacoronavirus SARS-CoV-2, the causative agent of COVID-19, has launched a race toward the characterization of SARS-CoV-2 infection in other animals (e.g., hamsters, cats, ferrets, bats, and monkeys), as well as adaptation of the mouse model, by modifying either the host or the virus. In the present study, we utilized a natural pathogen of mice, MHV, as a prototype to model betacoronavirus-induced acute lung injury and multiorgan involvement under biosafety level 2 conditions. We showed that C57BL/6J mice intranasally inoculated with MHV-3 develops severe disease, which includes acute lung damage and respiratory distress that precede systemic inflammation and death. Accordingly, the proposed animal model may provide a useful tool for studies regarding betacoronavirus respiratory infection and related diseases.

**KEYWORDS** betacoronavirus, MHV-3, lung infection, COVID-19, animal model, tumor necrosis factor

The Betacoronavirus genus belongs to the Coronaviridae family and encompasses positive-stranded enveloped RNA viruses. This viral group is broadly distributed among humans and other mammals, including rodents, bats, pigs, and ruminants (1–3). The high prevalence of betacoronaviruses all over the world, combined with their great genetic diversity and the increased human occupation of isolated ecosystems, makes the periodic emergence of novel coronaviruses in zoonotic outbreaks highly probable after host escape events (1). In fact, over the last 2 decades, there were three isolated zoonotic outbreaks of severe coronavirus infection in humans, including the currently circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic (4). Due to their epidemiological importance, a deeper understanding of viral biology, pathogenesis, and the discovery of therapeutic options against betacoronaviruses is imperative.

COVID-19 has a broad spectrum of clinical manifestations. While in most cases, SARS-CoV-2 respiratory infection is silent or triggers only mild respiratory symptoms, in others it leads to severe conditions, including acute respiratory distress syndrome (ARDS), systemic inflammation, multiorgan failure, and death (5, 6). Several animal models have been proposed as preclinical platforms to study the pathogenesis of SARS-CoV-2, including mice, ferrets, Syrian hamsters, and primates (7–12). The inherent resistance of wild-type mice to SARS-CoV-2 infection led to the establishment of strategies to adapt these rodents to infection by modifying either the host or the virus (9, 13, 14). One of the most common strategies has been the infection of transgenic mice expressing human ACE2 (hACE2) using SARS-CoV-2 strains. However, these animal models in general fail to reproduce the prolonged pneumonia with severe manifestations and multiorgan impairment, besides displaying a high rate of SARS-CoV-2 replication in nontarget tissues (15, 16). Due to interspecies differences, a set of diverse models is necessary for a broader understanding of viral tropism, replication, dissemination, clinical signs, pathogenesis, and immune response caused by SARS-CoV-2 (17).

The use of other betacoronaviruses, such as the murine coronavirus, has been suggested as a strategy to emulate many of the key aspects of human coronavirus infection (18, 19). Among murine coronaviruses, the group known as murine hepatitis coronavirus (MHV) is the prototype of this genus and a natural pathogen of the *Mus musculus* species (20). MHV is capable of inducing a severe and lethal disease in mice,
and some of its variants, such as MHV-1 and MHV-A59, may have an initial pulmonary tropism when inoculated intranasally, before systemic dissemination. Thus, targeting MHV respiratory infection may constitute a promising preclinical platform to mirror betacoronavirus-induced pathophysiological features seen in humans, including severe acute respiratory syndrome (18, 19, 21). An important advantage of using this murine model is the requirement for biosafety level 2 (BSL2), which makes this model significantly less costly and safer for screening compounds of therapeutic interest.

The murine hepatitis virus strain 3 (MHV-3) has classically been described as a causative agent of severe hepatitis in several strains of mice (20). Due to its hepatotropism, the potential of this MHV strain to also cause respiratory disease during an intranasal infection has been poorly investigated. In this work, we showed that intranasal infection of wild-type mice with MHV-3 produced a transient respiratory disease with pulmonary functional impairment before leading to systemic inflammation, multiorgan injury, and death. We also showed that the MHV-3-induced pulmonary and extrapulmonary manifestations were dependent on tumor necrosis factor (TNF) signaling.

RESULTS

Intranasally delivered MHV-3 favors pulmonary viral replication in C57BL/6J mice. To characterize a mouse model of coronavirus-induced acute respiratory infection inside a BSL2 facility, 6- to 7-week-old C57BL/6J mice were inoculated via the intranasal route with $10^3$ PFU of MHV-3 and monitored daily for signs of illness (Fig. 1a). Following infection, mice underwent significant weight loss, which started on the third day postinfection (dpi), and they became moribund and died by 6 dpi (Fig. 1b and c). Male and female animals succumbed similarly to the disease, as their median survival times upon MHV-3 challenge were 5.5 and 6 days, respectively. MHV-3 infection was also lethal at a lower dose ($10^2$ PFU); however, there was a modest delay in weight loss and death compared to that observed at a higher inoculum (Fig. 1b and c).

Intranasal infection of mice with $10^3$ PFU led to progressive thrombocytopenia (Fig. 1d). The number of circulating leukocytes also decreased as the infection progressed and was mostly driven by the sharp lymphopenia observed from 3 dpi onwards (Fig. 1d and e). Thermal response to viral infection was also observed. As depicted in Fig. 1f, body temperature began to rise slowly 24 h after virus inoculation. At 2 and 3 dpi, mice reached $37.4 \pm 0.3^\circ$C and $38.1 \pm 0.2^\circ$C, respectively, both of which were significantly higher than the average temperature recorded over 3 days before infection ($36.3 \pm 0.1^\circ$C; $P < 0.05$) (Fig. 1f and g). It is worth noting that major changes in body temperature occurred during the light phase, which is the resting period for nocturnal habit animals (Fig. 1g).

To ascertain whether intranasal delivered MHV-3 favors viral replication in the respiratory system, viral load was assessed in the lung at 1, 3, and 5 dpi and compared with that found in the plasma, liver, spleen, heart, kidney, brain, and testes. Results confirmed the lungs as the initial replication site of MHV-3, as assessed by the presence of infectious virus in this tissue, with viral loads significantly increasing from 1 dpi to 5 dpi (Fig. 1h). Conversely, viruses were recovered from 3 dpi onwards in other organs, with viremia being more stably detected at 5 dpi (Fig. 1h and i). Together, these data show that C57BL/6J mice are highly susceptible to intranasal inoculation of MHV-3 and that lungs are likely the primary site of viral infection and replication.

MHV-3 triggers inflammation-associated lung damage and respiratory dysfunction. We next investigated whether MHV-3 infection would affect lung morphology and trigger inflammation-associated tissue damage (Fig. 2a). Compared to mock controls, a higher number of cells stained for the panleukocyte marker CD45 was found in the lung sections of infected mice after 1 day and especially 3 days after inoculation (Fig. 3b). Flow cytometry results concurred with the recruitment of leukocytes to the lung tissue early during infection, showing a significant rise in the percentage of neutrophils and macrophages/monocytes. On the other hand, we found that the percentage of both CD4$^+$ and CD8$^+$ T cells in the lung gradually decreased as the infection progressed (Fig. 2c). The histopathologic examination of lung sections revealed that...
Intranasally inoculated MHV-3 triggers lethal disease in C57BL/6J mice. (a) Experimental design. (b) Body weight change upon infection assessed by two-way repeated-measures analysis of variance (ANOVA) plus Sidak’s multiple-comparison test (mean ± standard error of the mean [SEM]; n = 8). (c) Kaplan-Meier survival curve of infected mice versus mock controls (n = 8). (d) Changes in the number of circulating thrombocytes and leukocytes over 5 days postinoculation (dpi), represented as box plots. The whiskers go from the first and third quartiles to the minimum or maximum value. Data from each infection time were compared with those from the mock group by one-way ANOVA plus Dunnett’s multiple-comparison test (mean ± SEM; n = 10). (e) Differential blood count highlighting the sharp infection-related drop of lymphocyte counts that likely guided leukopenia noticed from 3 dpi onwards. Differences between infection groups and the mock control were assessed by one-way ANOVA plus Dunnett’s multiple-comparison test (mean ± SEM; n = 6). (f) Heatmap showing the body temperatures recorded in a group of 10 mice over 3 days pre- and postinfection. Note an increase in the mean temperature on 2 and 3 dpi, especially in the light phase. (g) Means ± SEM of body temperatures depicted in panel f according to the time of the day. (h, i) Viral load determined in organ extracts and plasma of MHV-3-infected mice by plaque assay. The results are presented as log_{10} PFU per gram of tissue or milliliter of plasma. Differences among groups were assessed by Kruskal-Wallis plus Dunn’s post hoc test (n = 5 to 8). LOD, limit of detection. ns, not significant (P > 0.05); *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
MHV-3 infection triggers inflammation-associated lung injury. (a) Experimental design. (b) Representative confocal three-dimensional (3D) image showing high abundance of CD45⁺ leukocytes (green staining) in the lungs of mice at 1 and 3 dpi. (c) Flow cytometry analyses showing the (Continued on next page)
MHV-3 infection triggered transient inflammation-associated lung injury. As such, approximately 50% of mice had discrete inflammatory cell infiltration in close association with areas of alveolar edema and hyperemic vessels at 1 day after MHV-3 infection (Fig. 2d to f). At 3 dpi, the inflammatory infiltrate became robust and widespread throughout the lung tissue, leading to greater histopathological changes. Inflammation foci were frequently seen in the vicinity of bronchioles, in perivascular areas, and in the lumen of hyperemic vessels (Fig. 2b, d, e, and f). Some blood vessels presented eosinophilic fibrillar material adherent to the vascular wall, which is characteristic of fibrin thrombi. In some samples, areas of necrosis and hemorrhage were also observed (Fig. 2d). Conversely, the inflammation-associated lung damage in the mouse lung at 5 dpi was milder and encompassed the changes portrayed here for day 1 after infection (Fig. 2d to f), suggesting that inflammation was resolving.

The intrapulmonary concentration of major chemokines (CCL2, CCL3, CCL4, and CCL5) and cytokines (TNF, interleukin 6 [IL-6], IL-1β, IL-12, and gamma interferon [IFN-γ]) was markedly increased at 1 dpi and/or 3 dpi and decreased thereafter (Fig. 2g). In contrast, high levels of the inflammatory mediators (IL-6, IL-10, TNF, IL-1β, and IFN-γ) were only detected in the blood at 5 dpi (Fig. 2h). These data suggest that the current infection model exhibits transient pulmonary pneumonia followed by systemic inflammation.

Next, we asked whether these histopathological changes could impact lung function. By using the whole-body plethysmography method, two control preinfection measurements of ventilatory parameters were performed in freely moving mice and compared with that recorded on 3 dpi (Fig. 3a). Interestingly, there was an increase in respiratory frequency in MHV-3-infected animals (Fig. 3b) that was characterized by shortened respiratory cycles (expiration/inhalation event; see Fig. 3b). In addition, the mechanics of the respiratory system were evaluated invasively in another group of mice at 3 dpi and compared to those of mock controls (Fig. 3a). There was restricted lung distention after MHV-3 infection, as determined by the lower static compliance of the respiratory system (Fig. 3c). There was also a decrease in vital capacity of the infected group (Fig. 3c). These restrictive aspects of pulmonary function are likely secondary to the pulmonary inflammation and damage. These data suggest that intranasal inoculation of MHV-3 in C57BL/6J mice triggers dysfunction of the respiratory system.

Given the pivotal role of diaphragm contraction for breathing and the recent evidence that SARS-CoV-2 might trigger diaphragm myopathy (22), we next checked the integrity of diaphragm neuromuscular junctions (NMJs) in the current infection model. By combining whole-mount confocal microscopy and computer-assisted image analysis, we showed that NMJs from MHV-3-infected mice at 3 and 5 dpi were significantly smaller and more fragmented at both pre- and postsynaptic endings compared to those of mock controls (Fig. 4). Although this deterioration of the diaphragm synaptic apparatus may not be sufficient to disrupt pulmonary ventilation in infected mice, we do not rule out the possibility that coronavirus-induced denervation at diaphragm NMJs could account for respiratory failure in the long term, which could be of particular interest for COVID-19 patients under mechanical ventilatory support.

MHV-3 induces extrapulmonary damage. MHV-3 is a murine coronavirus well-known for its hepatotropism (20). Overall, intranasally inoculated MHV-3 triggered hepatitis and liver necrosis, especially at 5 dpi (Fig. 5), the period that preceded systemic inflammation. We showed that in the plasma of infected mice, IL-6, IL-10, TNF, IL-1β, and IFN-γ concentrations were markedly increased at 1 dpi and/or 3 dpi and decreased thereafter (Fig. 2g). In contrast, high levels of the inflammatory mediators (IL-6, IL-10, TNF, IL-1β, and IFN-γ) were only detected in the blood at 5 dpi (Fig. 2h). These data suggest that the current infection model exhibits transient pulmonary pneumonia followed by systemic inflammation.
clinical manifestations and death of the animals (as shown in Fig. 1b and c). Consistent with the liver damage, liver function was heavily impaired at 5 dpi, as seen by the high serum levels of alanine aminotransferase (ALT) and the reduced hepatic ability to metabolize indocyanine dye at this time point (Fig. 5). Other organs, such as the brain, small intestine, and colon, had minimal to mild leukocyte infiltration at 3 and 5 dpi and were much less affected than the liver (Fig. 6).

Furthermore, in view of recent evidence pointing to the high susceptibility of the testes to both SARS-CoV and SARS-CoV-2 infection (23, 24), we evaluated whether MHV-3 could trigger testicular damage. Interestingly, the percentage of altered seminiferous tubules increased significantly after inoculation. The altered sites displayed epithelium sloughing, elevated germ cell apoptosis, and retention of residual bodies (Fig. 6c and d). Also, there appeared to be an increase in the volumetric density of blood vessels and lymph space in the testis interstitium of infected mice (Fig. 6d to f), although such changes did not attain statistical significance. Together, these results indicate that intranasal inoculation of MHV-3 triggers multisystem changes beyond the transient lung damage.

**TNF signaling abrogation significantly reduces lung injury and improves survival in MHV-3-infected mice.** Increasing concentrations of TNF have previously been associated with tissue damages triggered by MHV and human coronaviruses and are currently thought to aggravate COVID-19 severity (6, 25–27). Once this cytokine was
found here along with other proinflammatory mediators at higher levels within the lung of infected mice (Fig. 2g), we next interrogated the contribution of TNF signaling to the respiratory pathogenesis of MHV-3 infection. To this end, we intranasally infected mice genetically deficient for TNF receptor type 1 (TNFR1, also known as p55) with 10^3 PFU of MHV-3 and compared them with wild type (WT) mice. Strikingly, TNFR1 knockout (KO) mice were protected from abrupt weight loss and lethality, with 100% of mice surviving by the end of the 14-day follow-up period (Fig. 7a and b). The progressive leukopenia and thrombocytopenia phenotype observed in infected WT mice were not found in TNFR1 KO mice (Fig. 7c). Moreover, compared to the WT group, mice in the TNFR1 KO group had significantly lower viral loads (Fig. 7d), inflammation, and injury in their lungs (Fig. 7e to g).

To verify whether such a protective profile against MHV-3 could also be achieved using pharmacological approaches, WT mice were first infected intranasally with 10^3 PFU and then treated with etanercept, a selective TNF inhibitor (Fig. 8a). Regardless of the treatment route, etanercept did not prevent, but delayed, body weight loss (Fig. 8b). Similar findings were seen when survival rates were compared among groups, with etanercept-treated mice living 3 days longer on average than the untreated ones (vehicle group) (Fig. 8c). It is worth noting that both the local and systemic treatments with etanercept were capable of inhibiting MHV-3 replication in the lungs, with infectious viruses no longer detected in the majority of animals (Fig. 8d). Consistently, the inflammation-associated lung damage and overproduction of proinflammatory cytokines triggered by MHV-3 infection were substantially prevented with etanercept treatment, irrespective of the route of administration (Fig. 8e to g). Taken together, these findings reinforce an important contribution of the TNF pathway to the pathogenesis of respiratory coronavirus infection in mice.

Blocking TNF decreases SARS-CoV-2 replication and related cellular damage and proinflammatory cytokine production in human lung cells. We next evaluated the effects of etanercept treatment upon SARS-CoV-2 infection in vitro. For this, the human epithelial lung cell line Calu-3 was infected with SARS-CoV-2 and then treated

---

**FIG 4** Neuromuscular junctions (NMJs) from diaphragm muscle are smaller and more fragmented in MHV-3-infected mice. (a) Three-dimensional confocal images from whole-mount diaphragm showing presynaptic (green) and postsynaptic terminals (red) at NMJs following 3 days of infection. Bar, 50 μm. (b) Representative images from skeletonization and particle analysis of the NMJ highlighted in figure a by dotted squares. Red numbers indicate fragmentation points. (c) Quantification of the area occupied by presynaptic and postsynaptic terminals. In total, 125 NMJs per group were considered in this analysis, and the values from infected animals were compared with those from mock controls by one-way ANOVA plus Dunnett’s multiple-comparison test. (d) Quantification of the fragmentation percentages found in presynaptic and postsynaptic endings identified by particle analysis. Assessed by one-way ANOVA plus Dunnett’s multiple-comparison test (n = 5). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
with etanercept at different concentrations (0.5, 1, 5, and 10 ng/ml) (Fig. 9a). The results showed that etanercept treatment reduced the SARS-Cov-2-mediated cellular damage in a dose-dependent manner (Fig. 9b). Etanercept at 5 and 10 ng/ml had also a slight but statistically inhibitory effect on SARS-CoV-2 (Fig. 9c). Moreover, the overproduction of TNF, IL-8, and IL-18 triggered by SARS-CoV-2 infection was significantly reduced in Calu-3 cells treated with etanercept (Fig. 9d). These results suggest that TNF blocking by pharmacologic approaches might also be beneficial against SARS-CoV-2 infection in human lung epithelial cells.

**DISCUSSION**

The recent emergence and continuing spread of SARS-CoV-2 all over the world have launched a race toward the establishment of suitable in vivo platforms for evaluating vaccines and antiviral agents against human betacoronavirus (17). Here, we showed that the murine betacoronavirus MHV-3, despite its hepatotropism, may serve as a prototype to recapitulate, in wild-type mice, the many aspects of the respiratory disease and systemic alterations seen in patients with moderate or severe COVID-19. MHV-3 efficiently replicated in the lungs of C57BL/6J mice and triggered a robust inflammatory response, including accumulation of neutrophils and macrophages/monocytes accompanied by augmented tissue concentrations of proinflammatory cytokines and chemokines.

MHV-3 induced major lung histopathological changes, including alveolar edema, hemorrhage, and fibrin thrombi, which translated to functional alterations. Others betacoronaviruses might trigger transient pneumonia in wild-type mice, including the murine strains MHV-1, MHV-AS9, and MHV-S (20, 21), as well as mouse-adapted SARS-CoV-2.
strains (15, 16); however, their impact on respiratory mechanics has scarcely been evaluated. Here, we showed that pulmonary ventilation was increased in MHV-3-infected mice supported by an augmented respiratory frequency (i.e., tachypnea) without significant alteration in tidal volume. The augmented ventilation may be a result of the hypoxemia-induced ventilatory reflex response, mediated by chemoreceptors (28). Although

![Figure 6](image_url)

**FIG 6** Extrapulmonary changes triggered by MHV-3 inoculated via the intranasal route. (a) H&E staining of the brain, small intestine, and colon sections showing mild signs of inflammatory injury in infected mice. Original magnification, ×400. (b) Mean injury scores compared among groups by Kruskal-Wallis plus Dunn’s post hoc test (n = 5 or 6). (c) Toluidine blue staining of testicular cross sections showing morphological alterations in infection groups. ST, seminiferous tubule; IC, intertubular compartment; *, epithelium sloughing. Arrowheads indicate germ cell apoptosis, reddish lines indicate blood vessels, and bluish lines indicate lymph space. Bar, 50 μm. (d and e) Comparative morphometric analysis conducted in the tubular (d) and intratubular (e and f) compartments of mock versus MHV-infected mice. Assessed by one-way ANOVA plus Tukey’s post hoc test (mean ± SEM; n = 5). ns, not significant (P > 0.05); *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
we have not directly measured arterial blood gases, the lung pathologies of infected mice (alveolar edema, hyperemic vessels, and the presence of vessels with thrombi) strongly suggest deficits in gas exchange, provoked by dysfunctional diffusion and ventilation-to-perfusion ratio. The breathing pattern found in the infected mice, i.e., tachypnea-mediated increased ventilation, was well correlated with alterations of the mechanical properties of the respiratory system. Infected mice presented lower respiratory compliance that is suggestive of restrictive lung dysfunction. This sort of alteration is also described at least in some COVID-19 patients (29). From the viewpoint of respiratory work, a stiffened system (low compliance) augments the elastic work of breathing, and hence, increasing ventilation by a large tidal volume is energetically expansive and tachypnea is the prevailing breathing pattern in these circumstances (30, 31).
FIG 8 Pharmacologic blockade of TNF cytokine inhibits MHV-3 replication and inflammation-associate injury in the lungs of WT mice. (a) Experiment design. Following 24 h of MHV-3 inoculation, the animals received 2 mg/kg of etanercept or saline (vehicle) twice daily via the intranasal (i.n.; local treatment) or intraperitoneal (i.p.; systemic treatment) route. Treatment schedule was kept for 10 days in a group of animals to assess body weight change and lethality, whereas in another group, samples were collected at 3 dpi. (b) Profile of body weight change among groups. Differences between vehicle and etanercept groups were assessed according to the treatment route by two-way repeated measures ANOVA plus Sidak’s multiple-comparison test (mean ± SEM; n = 8). (c) Kaplan-Meier survival analysis of MHV-3-infected mice treated with etanercept versus vehicle controls (n = 8). (d) Viral load determined by plaque assay at 3 dpi in the lung of MHV-3-infected mice treated or not with etanercept Statistical differences were assessed using the Mann-Whitney test (n = 5). LOD, limit of detection. (e) H&E staining of lung sections showing reduction of inflammation-associated injury signs in etanercept group versus vehicle controls at 3 dpi. Bar, 50 μm. (f) Comparative histopathology of lungs according to groups (Mann-Whitney test; n = 5). (g) Concentrations of TNF, IFN-γ, IL-1β, and IL-6 measured by ELISA in the lung of MHV-3-infected mice treated or not with etanercept. The values were normalized to the mock group and presented as percentage of mock controls (mean ± SEM). Assessed by Mann-Whitney test, n = 7 or 8. ns, not significant (P > 0.05); *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Moreover, the infection-elicited symptoms in mice described here, fever and tachypnea, recapitulate symptoms described in some COVID-19 patients (32, 33). It is noteworthy that after inducing pulmonary changes, MHV-3 spread to multiple organs and triggered a systemic and lethal disease. Although the host receptor used for virus entry differs between murine and human coronaviruses (34, 35), the dissemination of MHV-3 to extrapulmonary sites and the subsequent systemic hyperinflammation with high circulating levels of TNF, IFN-γ, IL-1β, and IL-6 may provide a substantial platform to understand the mechanisms underlying the systemic inflammatory response syndrome (SIRS) and multiple organ failure (14, 36).

TNF has an important role in the coordination and development of most overexuberant inflammatory responses (6, 25, 26), and its inhibition can alleviate acute lung injury caused by severe respiratory syncytial virus and influenza virus (37, 38). During betacoronavirus infection, the overt TNF release can act synergically with IFN-γ and trigger robust inflammatory cell death (39, 40). Increasing studies in both MHV and SARS-CoV-2 have demonstrated that overt proinflammatory release, including TNF, is mediated by the host Toll-like receptor (TLR2)-Myd88 cascade (26, 41). Therefore, targeting either TNF or TLR2 blockade may provide substantial protection against the pathogenesis of coronavirus infection (39, 41). TNF has already been described as an important cytokine involved in inducing liver damage after intraperitoneal MHV-3 infection in mice (27). In this work, TNF was also associated with the induction of lung damage after intranasal infection with MHV-3. We showed that TNFR1 KO infected mice were fully protected from lung tissue injury and death. In line with this, treating infected wild-type mice with etanercept, a selective TNF inhibitor, mitigated the MHV-3-induced cytokine release and tissue damage in lungs. Moreover, we have shown that etanercept can also significantly decrease the cellular damage and proinflammatory cytokine release triggered by SARS-CoV-2 infection, in vitro. Although this preliminary result needs to be further confirmed by distinct in vitro and in vivo models of SARS-CoV-2 infection, it suggests that TNF blocking may alleviate the pathogenesis of betacoronavirus infection.

**FIG 9** TNF blocking decreases SARS-CoV-2 replication and related cellular damage in human lung epithelial cells. (a) Experiment design. (b) Measurement of cell damage by dosing lactate dehydrogenase (LDH) levels released in cell supernatant of Calu-3 cells treated or not with different concentration of etanercept. (c) Changes in SARS-CoV-2 viral load determined in Calu-3 cells supernatants after treatment with increasing doses of etanercept. (d) ELISA showing lower concentrations of TNF, IL-6, and IL-8 in infected Calu-3 cells following etanercept treatment. Values from each dose group were compared to those from untreated controls by one-way ANOVA plus Dunnett’s multiple-comparison test. n = 3 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
In summary, MHV-3 intranasal infection produced pathological features of severe acute respiratory syndrome in wild-type mice and translated into efficient virus replication in the lungs, induction of inflammation-associated tissue damage, and functional impairment of the respiratory function. Moreover, following respiratory manifestations, MHV-3 spread to distant organs and led to systemic inflammation and death, which enable the use of this mouse model for studying betacoronavirus-induced systemic alterations. Akin to other animal models already proposed for COVID-19 study, the MHV-3 model has limitations. One of them is the difference in the host cell receptor used for viral entry. All MHV strains uses the CEACAM-1 receptor (34), whereas SARS-CoV-2 uses ACE2 (35), which may preclude studies of viral entry or drugs that act on this stage of the replication cycle. Another important limitation is the strong viral tropism to extrapulmonary sites following 3 days of infection, which shortens the time window to assess unique pulmonary changes caused by MHV infection. In particular, the liver was severely affected at 5 dpi, at which necrotic areas could be frequently seen in the parenchyma. Although signs of liver injury (e.g., elevated levels of aminotransferases) have frequently been reported for COVID-19 patients and may be associated with disease severity (42), the MHV-induced hepatic changes seem to be greater in magnitude than those triggered by SARS-CoV-2. Thus, caution must be given to using the proposed model to understand the gastrointestinal manifestations of human betacoronavirus infections. Similarly, drugs that rely on the metabolism by hepatic enzymes should have their action limited at late time points of MHV-3 infection.

MATERIALS AND METHODS

Cells, viruses, and plaque assay. L929 (ATCC CCL-1), Vero E6 (ATCC CRL-1586), and Calu-3 (ATCC HTB-55) cells were cultured under a controlled atmosphere (37°C and 5% CO₂) in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, Vero and L929) or minimal essential medium (MEM) (Calu-3) supplemented with 7% fetal bovine serum (FBS) and 100 µg/ml streptomycin. The MHV-3 strain was provided and sequenced (GenBank accession no. MW620427.1; see reference 43) by Clarice Weis Arrn and Ricardo Duñes-Carvalho from the Universidade Estadual de Campinas (UNICAMP, Brazil), and propagated in L929 cells. SARS-CoV-2 was expanded in Vero E6 cells from an isolate obtained from a nasopharyngeal swab obtained from a confirmed case of COVID-19 in Rio de Janeiro, Brazil (GenBank accession no. MT710714), according to WHO guidelines. For viral titration, 100 µl of serially diluted virus suspension, plasma samples, and tissue homogenates (1:9 tissue to DMEM) were inoculated onto a confluent monolayer of L929 cells (for MHV-3) or Vero E6 cells (for SARS-CoV-2) grown in 24-well plates. After gentle shaking for 1 h (4 × 15 min), samples were removed and replaced with the overlay medium (DMEM containing 0.8% carboxymethylcellulose, 2% FBS, and 1% penicillin-streptomycin-glutamine) and kept for 2 days (for MHV-3) or 3 days (for SARS-CoV-2), at 37°C and 5% CO₂. Then, cells were fixed with 10% neutral buffered formalin (NBF) for 1 h and stained with 0.1% crystal violet. Virus titers were determined as PFU.

Mouse strains. Animal experimental procedures were carried out with mixed groups (males and females) of mice aged 6 to 7 weeks and received the approval of the Ethical Committee for Animal Experimentation of the Universidade Federal de Minas Gerais (UFMG) (process no. 190/2020). Wild-type C57BL/6 (Central Animal House of the UFMG) and TNF receptor knockout mice (TNFRp55−/−; stock no. 002818; Jackson Laboratories) were housed in individually ventilated cages placed in an animal care facility at 24°C ± 2°C on a 12-h light/12-h dark cycle, receiving ad libitum access to water and food.

MHV-3 infection. Mice were lightly anesthetized (ketamine [50 mg/kg]-xylazine [5 mg/kg], intraperitoneally [i.p.]) and received an intranasal inoculation of 30 µl sterile saline solution, loaded or not (mock controls) with MHV-3 at different concentrations (3 × 10⁵ to 3 × 10⁶ PFU). Signs of disease, including ruffled fur, back arching, weight loss, facial edema, and lack of activity were monitored daily for up to 14 days postinoculation (dpi).

Sample collection. Following anesthesia (ketamine [80 mg/kg]-xylazine [10 mg/kg], i.p.), the animals were euthanized by cervical dislocation, and blood samples were collected from the abdominal vena cava and analyzed. The lungs were then harvested, and the right lobes were snap-frozen in liquid nitrogen, whereas the left lobes were fixed in 10% neutral buffered formalin, unless otherwise mentioned. Formalin-fixed and frozen fragments of other target tissues were also collected for additional analyses.

Hematological evaluation. The number of circulating thrombocytes and leukocytes was determined in blood samples using the a Celltac MEK-6500K hemocytometer (Nihon Kohden).

Histopathology. Formalin-fixed and paraffin-embedded (FFPE) tissues were sectioned into 5-µm thickness slices, stained with hematoxylin and eosin (H&E), and examined under light microscopy. The inflammation-mediated injury in mouse lungs was determined by a pathologist (C.M.O.-J) who was blind to the experimental conditions, employing a scoring system encompassing (i) airway inflammation (up to 4 points), (ii) vascular inflammation (up to 4 points), (iii) parenchyma inflammation (up to 5 points), and general neutrophil infiltration (up to 5 points) (44). Histopathological assessments were also performed in FFPE samples of liver, brain, small intestine, and colon, following previously established...
Cytokine and chemokine dosage. Mouse lung homogenates were acquired by homogenizing 40 mg of frozen tissue in 400 ml of chilled cytokine extraction buffer (100 mM Tris [pH 7.4], 150 MM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, and 1% protease inhibitor cocktail). After centrifugation (14,000 × g, 15 min, 4°C), the supernatant was collected and submitted to a dosage of TNF, IFN-γ, IL-10, IL-6, IL-1β, IL-12 p70, CXCL-1, CCL-2, CCL-3, CCL-4, or CCL-5 using the mouse DuoSet enzyme-limited immunosorbent assay (ELISA) system (R&D Systems). Plasma concentrations of TNF, IFN-γ, IL-10, and IL-6 were also determined.

Immunofluorescence. Lung tissues were flushed with OCT/4% paraformaldehyde solution and processed for OCT embedding. The cryosections (15-μm thickness) were permeabilized with phosphate-buffered saline (PBS)/0.5% Triton X-100, incubated for 1 h in the blocking solution (PBS containing 5% goat serum and 5 μg/ml mouse BD FC Block) and then labeled overnight at 4°C with the allopurinol conjugated anti-Mouse CD45 antibody (APC-Cy5.5 conjugated anti-Mouse CD45; BD Pharmingen) and then stained using 4′,6-diamidino-2-phenylindole (DAPI; 1 μg/ml, catalog no. D9542; Sigma-Aldrich). Fluorescent signals were evaluated by confocal microscopy using an inverted Nikon Eclipse Ti microscope coupled to an A1 scanning head.

Flow cytometry. Lungs were minced into small pieces and allowed to digest with gentle agitation (80 rpm, 37°C, 45 min) onto cannula tubes containing 5 ml of digestion buffer (0.5 mg/ml collagenase and 20 mg/ml DNase diluted in RPMI medium). After, the cell suspension was passed through the cell strainer (pore size, 70 μm; BD Biosciences, San Jose, CA), and the remaining erythrocytes were lysed with ACK buffer (Invitrogen, Carlsbad, CA). Cells (1 × 10^6) were blocked with mouse BD FC Block (5 μg/ml, catalog no. 553141; BD Pharmingen) and then stained using fluorescence-labeled monoclonal antibodies, as follows: Ly6G-FITC (1:200, catalog no. 127627; BioLegend); CD45-fluorescein isothiocyanate (FITC) (1:200, catalog no. 5330801; BD Pharmingen); F4/80-phycocerythrin (PE)-Cyanine 7 (1:100, catalog no. 25-4801-82; Invitrogen); CD4-PE (1:100, catalog no. 100408; BioLegend); CD3-PerCP-Cyanine 5.5 (1:100, catalog no. 100218; BioLegend); CD8-allophycocyanin (APC) (1:100, catalog no. 17-0081-82; Invitrogen). The acquisition was carried out in a BD FACSCanto II cell analyzer and analyzed using FlowJo software (Tree Star, Ashland, OR).

Liver function analyses. Serum concentrations of alanine aminotransferase (ALT) and indocyanine green (ICG) were used to estimate the liver function status, as previously described (50). In addition, liver necrosis was evaluated by intravitral microscopy after labeling free DNA. To this end, 20 min before imaging, mice received an intravenous injection of 1 mg Sytox orange diluted in 0.1 ml of sterile saline solution (51).

Measurement of body temperature. Ten days before MHV-3 infection, a group of 10 mice underwent surgery to implant a temperature probe (mini dataloggers; SubCue, Calgary, AB, Canada) into the abdominal cavity. The probes were programmed to start recording data at 7 a.m. on the first day after infection animals were deeply anesthetized until respiratory arrest. Mice were tracheostomized and a polyethylene tube (P50) was inserted into the trachea. The pressure-volume curve was made by injecting air volume in a stepwise manner (using the 3-ml glass syringe), with 0.1-ml increments until intratracheal pressure peaked at approximately 35 cmH2O. In the deflation limb, the system was deflated in the same volume steps until the pressure reached approximately −15 cmH2O and finally inflated again to resting lung volume. Signals were acquired and recorded on the PowerLab software (LabChart v. 7; ADInstruments, NSW, Australia). The pressure-volume curve was calculated as the product of the tidal volume (ml body temperature and pressure, saturated [BTPS] · g−1; see reference 52) and respiratory frequency (breath cycles · min−1), corrected by the body weight (g). From the ventilatory recording traces, the inspiration and expiration time, as well as total respiratory cycle duration, were also calculated.

Respiratory mechanics. Mice were divided into two groups (mock n = 9 and infected n = 11) and 3 days postinfection animals were deeply anesthetized until respiratory arrest. Mice were tracheostomized and a polyethylene tube (P50) was inserted into the trachea. The pressure-volume curve was made by injecting air volume in a stepwise manner (using the 3-ml glass syringe), with 0.1-ml increments until intratracheal pressure peaked at approximately 35 cmH2O. In the deflation limb, the system was deflated in the same volume steps until the pressure reached approximately −15 cmH2O and finally inflated again to resting lung volume. Signals were acquired and recorded on the PowerLab software (LabChart v. 7; ADInstruments, NSW, Australia). The vital capacity was determined by maximal inflation (lung volume at 35 cmH2O), and the static compliance of the total respiratory system (expressed as ml/cmH2O) was measured at the steepest point of the deflation limb of the pressure-volume curve.

Neuromuscular junction analysis of diaphragm muscle. Whole-mount diaphragms were used to evaluate changes in neuromuscular junctions (NMJs) of MHV-3-infected mice and mock controls. Sample processing and labeling of NMJs were performed based on a previous protocol (53). The presynaptic and postsynaptic terminals were stained using the monoclonal anti-synaptotagmin antibody (1:250 dilution, catalog no. 3H2 2D7; Developmental Studies Hybridoma Bank) and the tetramethylrhodamine-conjugated α-bungarotoxin (1:1,000 dilution, catalog no. T1175; Invitrogen), respectively. After Z-stack imaging in a Zeiss LSM 880 confocal microscope, 25 NMJs per animal were assessed by particle analysis to estimate the fragmentation index at pre- and postsynaptic endings (54).
Etanercept treatment. For in vivo TNF inhibition, C57BL/6J WT mice were intranasally inoculated with 1 × 10^6 PFU of MHV and received 2.5 mg/kg of etanercept (Enbrel; Pfizer) twice a day delivered in 30 μl sterile saline solution via the nasal route (local treatment scheme) or intraperitoneally (systemic treatment scheme). Treatments started following 6 h after infection and lasted until 6 dpi. The vehicle groups received only saline solution.

TNF inhibition was also tested in vitro against SARS-CoV-2. To this end, Calu-3 cells were seeded onto 24-well plates and infected with SARS-CoV-2 (multiplicity of infection [MOI] 0.1). The control group was kept uninfected. After 1 h of viral adsorption, the medium containing virus was replaced for fresh medium loaded with increasing concentrations of Etanercept (0.5, 1, 5, and 10 ng/ml). Following 48 h of treatment, the Calu-3 supernatant was collected for measuring virus load as well as the concentration of target cytokines and lactate dehydrogenase (LDH).

Statistical analyses. Prism 8.0 software (GraphPad) was used for statistical analysis. First, data distribution was assessed by the Shapiro-Wilk test and Q-Q plots. Parametric comparisons between two or more groups were done using Student’s t test or one-way analysis of variance (ANOVA), respectively, or by using a Mann-Whitney or Kruskal-Wallis test to assess differences between two or more nonparametric data sets. Survival rates among groups were determined by Kaplan-Meier survival analysis. Finally, the body weight changes triggered by MHV-3 were compared among groups by two-way repeated-measures ANOVA. Data are presented as mean ± standard error of the mean (SEM). Differences with a P value of <0.05 were considered statistically significant.

ACKNOWLEDGMENTS

This work was financially supported by grants from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior–CAPES/Brazil (grant 88887.507173/2020-00 to M.M.T.), JBS-INVITARE/Brazil (grant 27991 to M.M.T.), Fundação de Amparo à Pesquisa do Estado de São Paulo–FAPESP/Brazil (grant 2019/01255-9 to R.D.-C.), a Ferring COVID-19 Investigational Grant (grant FIN0042393 to G.M.J.C.), and the L’Oréal-Unesco-ABC For Women in Science Program (grant to V.V.C.). This work also received support from the National Institute of Science and Technology in Dengue and Host-Microorganism Interaction (INCT em Dengue), sponsored by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; Brazil) and the Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG; Brazil).

We also acknowledge Leda Quercia Vieira for the donation of the TNFR1 KO mice and Ilma Marçal de Souza for her technical assistance with experiments.

Author contributions were as follows. Study design: A.C.D.S.P.A., G.H.C.-S., C.M.Q.-J., L.C.D.O., L.P.D.S., M.M.T., G.S.F.D.S., and V.V.C. Intellectual, P.A.C.V., L.R.-O., M.M.A., A.F.A.F., N.T.W., A.C.F., J.R.T., and A.C. Data analysis: A.C.D.S.P.A., G.H.C.-S., C.M.Q.-J., L.C.D.O., L.D.S.B.L., J.C.P., F.R.O.D.S., I.D.M.C., I.B.P., D.C.T., P.G.B.-S., L.C.D.O., L.P.D.S., M.M.T., G.S.F.D.S., and V.V.C. Performed experiments: A.C.D.S.P.A., and Ilma Marçal de Souza for her technical assistance with experiments.

We declare no competing financial interest in relation to this work.

REFERENCES

1. Cui J, Li F, Shi ZL. 2019. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181–192. https://doi.org/10.1038/s41579-018-0118-9.
2. Boni MF, Lemey P, Jiang X, Lam TTY, Perry BW, Castoe TA, Rambaut A, Robertson DL. 2020. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat Microbiol 5:1408–1417. https://doi.org/10.1038/s41556-020-0777-4.
3. Wang W, Lin XD, Zhang HL, Wang MR, Guan XQ, Holmes EC, Zhang YZ. 2020. Extensive genetic diversity and host range of rodent-borne coronavirus. Virus Evol 6:veaa078. https://doi.org/10.1093/ve/veaa078.
4. Lu R, Zhao X, Xiao J, LiQ, LiuP, YangB, WangW, SongH, HuangB, ZhuN, BiY, MaX, ZhanH, ZhangL, WangL, GuanQ, HolmesEC, ZhangYZ. 2020. Genome characterization and epidemiology of 2019 novel coronavirus: implications for virus origin and receptor binding. Lancet 395:565–574. https://doi.org/10.1016/S0140-6736(20)30251-8.
5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497–506. https://doi.org/10.1016/S0140-6736(20)30189-3.
6. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekeen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. 2020. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 26:1636–1643. https://doi.org/10.1038/s41591-020-1051-9.
7. Gurumurthy CB, Quadros RM, Richardson GP, Poluektova LY, Mansour SL, Ohtsuka M. 2020. Genetically modified mouse models to help fight COVID-19. Nat Protoc 15:3777–3787. https://doi.org/10.1038/s41596-020-00403-2.
8. Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE, Earnest JT, Keeler SP, Ritter JH, Kang L, Dort S, Robichaud A, Head R, Holtzman MJ, Diamond MS. 2020. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol 21:1327–1335. https://doi.org/10.1038/s41590-020-0778-2.
9. Dinnon KH, Leist SR, Schäfer A, Edwards CE, Martinez DR, Montgomery SA, West A, Yount BL, Hou YJ, Adams LE, Guly KL, Brown AJ, Huang E, Bryant MD, Choong IC, Glenn JS, Gralinski LE, Sheahan TP, Baric RS. 2020. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586:560–566. https://doi.org/10.1038/s41586-020-2708-8.

10. Shi J, Chen G, Yang S, Wang R, Zhang X, Gao S, China 2019. J Ultrasound Med 40:1787–1788. https://doi.org/10.1002/jum.15558.

11. Shi X, Guan C, Chen R, Wang Y, Feng S, Wang R, Qu G, Zhao S, Wang F, Wang X, Zhang D, Liu L, Aiao A, Yuan S. 2021. Pathological and molecular examinations of postmortem tests biopsies reveal SARS-CoV-2 infection in the tests and spermatogenesis damage in COVID-19 patients. Cell Mol Immunol 18:487–489. https://doi.org/10.1038/s41423-020-00604-5.

12. Shao L, Yamamoto M, Kojima Y, Tsurugaya K, Sata T, Yamamoto N, Sasaki T, Ishizaka Y. 2008. Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry. Proc Natl Acad Sci U S A 105: 7809–7814. https://doi.org/10.1073/pnas.0711241105.

13. Jacques A, Bleau C, Turbide C, Beaucournu N, Lamontagne L. 2009. Macrophage interleukin-6 and tumour necrosis factor-α are induced by coronavirus fixation to Toll-like receptor 2/heparan sulphate receptors but not carrageenan cell adhesion antigen 1a. Immunology 128: e181–e192. https://doi.org/10.1111/j.1365-2657.2008.02946.x.

14. Wang J, Shuai L, Wang C, Liu R, He X, Shan D, Ge J, Wang X, Luo DY, Wang H, Yang X, Li Y, Han G, He Y, Zhou X, Sun Z, Sheng X, Jiang S, Sun Y, Qiu CF, You Y. 2020. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 369:1603–1607. https://doi.org/10.1126/science.abc4730.

15. Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Pu X, Pu Y, Qi F, Qu Y, Li F, Lv Q, Wang W, Xue J, Gong S, Liu M, Wang G, Wang S, Song Z, Zhao L, Liu P, Zhao L, Ye F, Wang H, Zhou W, Zhu N, Zhen W, Yu H, Zhang X, Guo L, Chen L, Chen W, Wang C, Wang Y, Wang X, Xiao Y, Sun Q, Liu H, Zhu F, Ma C, Yan L, Yang M, Han J, Xu W, Tan W, Peng X, Qin J, Wu G, Qin C. 2020. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583:830–833. https://doi.org/10.1038/s41586-020-2312-y.

16. Hahideh SN, Abdullah ML, Abuyassin B, Bouchama A. 2020. Evidence of a mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. J Virol 84:2013–2022. https://doi.org/10.1128/jvi.02289-19.

17. Xu H, Li L, Cao D, Wu Y, Chen Y. 2014. Tumor necrosis factor α (TNF-α) receptor-1 is required for TNF-α-mediated fulminant virus hepatitis caused by murine hepatitis virus strain-3 infection. Immunol Lett 158:25–32. https://doi.org/10.1016/j.imlet.2013.11.008.

18. Vapnik K, Akoumianaki E, Tellais I, Golicher EC, Brochard L, Georgopoulos D. 2020. Respiratory drive in critically ill patients: pathophysiology and clinical implications. Am J Respir Crit Care Med 190:2020–2032. https://doi.org/10.1164/rccm.201903-0596So.

19. Gattinoni L, Chiurollo D, Caiorni P, Busana M, Romitti B, Brazzi L, Camporota L. 2020. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med 46:1099–1102. https://doi.org/10.1007/s00134-020-06633-2.

20. Morin CM, JP. 2019. How to breathe: Respiratory mechanics and breathing pattern. Respir Physiol Neurobiol 261:48–54. https://doi.org/10.1016/j.resp.2018.12.005.

21. Rockx B, Küken T, Herfst S, Bestebroer T, Lamers MM, Munnink BB, De Meulder D, Van Amerongen G, Van Der Brand J, Okba NMA, Schipper D, Van Der Velden MF, Foucheur R, De Swart R, Koopmans M, Haagmans BL. 2020. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368:1015–1018. https://doi.org/10.1126/science.abb7314.

22. 2011. Coronavirus pathogenesis, p 85

23. 2010. Of mice and November 2021 Volume 95 Issue 22 e01276-21 jvi.asm.org

24. 2020. Ultrasound imaging findings of acute testicular infection in patients with coronavirus disease 2019. J Ultrasound Med 40:1787–1788. https://doi.org/10.1002/jum.15558.

25. Bauböck R, Matzle B, Stricker G, Becher M, Langermans J, Langermans J, Drosten C, Van Vliissingen MF, Foucheur R, de Swart R, Koopmans M, Haagmans BL. 2020. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368:1015–1018. https://doi.org/10.1126/science.abb7314.
40. Kariki R, Sharma BR, Tuladhar S, Williams EP, Zalduando L, Samir P, Zheng M, Sundaram B, Banoth B, Malreddy RKS, Schreiner P, Neale G, Vogel P, Webby R, Jonsson CB, Kanneganti TD. 2021. Synergism of TNF-α and IFN-γ Triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184:149–168.e17. https://doi.org/10.1016/j.cell.2020.11.025.

41. Zheng M, Kariki R, Williams EP, Yang D, Fitzpatrick E, Vogel P, Jonsson CB, Kanneganti TD. 2021. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol 22:829–838. https://doi.org/10.1038/s41590-021-00937-x.

42. Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J. 2020. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 73:807–816. https://doi.org/10.1016/j.jhep.2020.05.002.

43. Garcia AB, De Moraes P, Rodrigues DM, Gilioli R, de Oliveira-Filho EF, Durães-Carvalho R, Weis Arns C. 2021. Coding-complete genome sequence of murine hepatitis virus strain 3 from Brazil. Microbiol Resour Announc 10:e00248-21. https://doi.org/10.1128/MRA.00248-21.

44. Horvat JC, Beagley KW, Wade MA, Preston JA, Hansbro NG, Hickey DK, Kaiko GE, Gibson PG, Foster PS, Hansbro PM. 2007. Neonatal chlamydial infection induces mixed T-cell responses that drive allergic airway disease. Am J Respir Crit Care Med 176:556–564. https://doi.org/10.1164/rccm.200607-1005OC.

45. Costa VV, Fagundes CT, Rachid MA, Ryffel B, Zamboni DS, Teixeira MM. 2017. Muscle atrophy is associated with cervical spinal motoneuron loss in a murine model for Huntington's disease. Eur J Neurosci 45:785–796. https://doi.org/10.1111/ejnn.13510.